Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

20 novembre 2016 aggiornato da: GlaxoSmithKline

A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled Corticosteroids

A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This will be a multi-centre, randomised, placebo controlled (with rescue medication), double-blind, parallel group study. Subjects meeting all the inclusion criteria and none of the exclusion criteria during Visit 1 (Screening Visit) will enter a two week Run-in Period. Subjects failing screening will not be eligible for re-screening. During the run-in and double-blind treatment periods subjects will maintain an electronic daily diary to record morning and evening peak expiratory flow (PEF), asthma symptom score and rescue albuterol/salbutamol use. At Visit 2 (end of run-in/Randomisation Visit), subjects meeting the eligibility criteria will be randomised to either inhaled Fluticasone Furoate 50 mcg or inhaled placebo. In addition all subjects will be supplied with albuterol/salbutamol inhalation aerosol to use as required to treat symptoms. Subjects will attend 4 on-treatment visits at Visits 3, 4, 5, and 6 (Weeks 2, 4, 8 and 12 respectively). Subjects will receive treatment for 84 days (12 weeks). A follow-up contact will be performed 1-week after completing study medication (Visit 7). Subjects will participate in the study for up to a maximum of 15 weeks (including screening, treatment and follow-up contact).

Tipo di studio

Interventistico

Iscrizione (Effettivo)

248

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Federazione Russa
      • Klin, Federazione Russa, 141600
        • GSK Investigational Site
      • Moscow, Federazione Russa, 115446
        • GSK Investigational Site
      • Saratov, Federazione Russa, 410028
        • GSK Investigational Site
      • St. Petersburg, Federazione Russa, 194356
        • GSK Investigational Site
      • Voronezh, Federazione Russa, 394066
        • GSK Investigational Site
      • Yaroslavl, Federazione Russa, 150003
        • GSK Investigational Site
  • Messico
    • Jalisco
      • Zapopan, Jalisco, Messico, 45040
        • GSK Investigational Site
    • Michoacán
      • Morelia, Michoacán, Messico, 58070
        • GSK Investigational Site
    • Tabasco
      • Villahermosa, Tabasco, Messico, 86100
        • GSK Investigational Site
  • Perù
      • Lima, Perù, Lima 1
        • GSK Investigational Site
      • Lima, Perù, Lima 27
        • GSK Investigational Site
    • Lima
      • Lima 18, Lima, Perù
        • GSK Investigational Site
      • San Borja, Lima, Perù, Lima 41
        • GSK Investigational Site
      • San Miguel, Lima, Perù, Lima 32
        • GSK Investigational Site
  • Stati Uniti
    • California
      • Long Beach, California, Stati Uniti, 90808
        • GSK Investigational Site
      • Los Angeles, California, Stati Uniti, 90025
        • GSK Investigational Site
      • Newport Beach, California, Stati Uniti, 92663
        • GSK Investigational Site
    • Georgia
      • Albany, Georgia, Stati Uniti, 31707
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, Stati Uniti, 65203
        • GSK Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73103
        • GSK Investigational Site
    • South Carolina
      • Orangeburg, South Carolina, Stati Uniti, 29118
        • GSK Investigational Site
      • Spartanburg, South Carolina, Stati Uniti, 29303
        • GSK Investigational Site
    • Texas
      • Corsicana, Texas, Stati Uniti, 75110
        • GSK Investigational Site
      • Waco, Texas, Stati Uniti, 76712
        • GSK Investigational Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

12 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Signed informed consent
  • Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks before first visit
  • Both genders; females of child bearing potential must be willing to use appropriate contraception during the study
  • Pre-bronchodilator FEV1 of at least 60% predicted
  • FEV1 reversibility of at least 12% and 200mls
  • Current asthma therapy that includes a non-corticosteroid controller and/or short-acting beta agonist

Exclusion Criteria:

  • History of life-threatening asthma exacerbation within the past 10 years
  • Asthma exacerbation requiring treatment with oral corticosteroids within the last 3 months or that required overnight hospital stay within 6 months
  • Current or recent respiratory infection or current oral candida infection
  • Presence of another significant respiratory disease or medical condition that is not controlled or that could affect subject safety or study outcome
  • Known or suspected allergy to study drug or materials
  • Taking another investigational medication or prohibited medication during the study
  • Previous treatment with inhaled fluticasone furoate in a phase II or III study
  • Current smokers or former smokers with significant tobacco exposure
  • Children in Care

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Fluticasone furoate 50mcg
Inhalation powder delivered by Novel Dry Powder Inhaler
Droga: Fluticasone furoate 50mcg
Inhalation powder delivered by Novel Dry Powder Inhaler
Comparatore placebo: Placebo
Inhalation powder delivered by Novel Dry Powder Inhaler
Droga: Placebo
Inhalation powder delivered by Novel Dry Powder Inhaler

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period
Lasso di tempo: Baseline and Week 12
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Evening clinic visit FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the Week 12 clinic visit. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 were measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 2. Change from Baseline was calculated as the Week 12 value minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing, pre-dose, post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing value.
Baseline and Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 12-week Treatment Period
Lasso di tempo: From Baseline up to Week 12
The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. A 24-hour period was considered as missing if both day time and night time values were missing or if one of the day time or night time values were missing and the other value indicated no use of rescue medication. The Baseline value is the average of the values over the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
From Baseline up to Week 12
Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Lasso di tempo: From Baseline up to Week 12
PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough PM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
From Baseline up to Week 12
Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period
Lasso di tempo: From Baseline up to Week 12
PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
From Baseline up to Week 12
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 12-week Treatment Period
Lasso di tempo: From Baseline up to Week 12
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. A 24-hour period was considered as missing if both the day time and night time data were missing or if one was symptom-free but the other was missing. The Baseline value was the average of the values of the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
From Baseline up to Week 12
Number of Participants Who Withdrew Due to a Lack of Efficacy During the 12-week Treatment Period
Lasso di tempo: From the first dose of the study medication until Week 12/Early Withdrawal
The reason for withdrawal was lack of efficacy if a participant was withdrawn due to: clinic FEV1 falling below the FEV1 stability limit; participant experiencing at least 4 days of AM or PM PEF falling below the PEF stability limit and/or at least 3 days of >=12 inhalations/day of albuterol/salbutamol usage during the 7 days immediately preceding any contact; or the occurrence of an asthma exacerbation, defined as the deterioration of asthma requiring the use of systemic (oral, parenteral, or depot) corticosteroids for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. The FEV1 stability limit was calculated as the best pre-salbutamol/albuterol FEV1 at Visit 2 * 80%. The PEF stability limit was calculated as the mean AM PEF from the available 7 consecutive days preceding Visit 2 * 80%.
From the first dose of the study medication until Week 12/Early Withdrawal

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

GlaxoSmithKline

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 settembre 2011

Completamento primario (Effettivo)

1 giugno 2012

Completamento dello studio (Effettivo)

1 agosto 2012

Date di iscrizione allo studio

Primo inviato

15 settembre 2011

Primo inviato che soddisfa i criteri di controllo qualità

15 settembre 2011

Primo Inserito (Stima)

19 settembre 2011

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

11 gennaio 2017

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 novembre 2016

Ultimo verificato

1 novembre 2016

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 115283

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Sì

Descrizione del piano IPD

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Dati/documenti di studio

  1. Piano di analisi statistica
    Identificatore informazioni: 115283
    Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
  2. Specifica del set di dati
    Identificatore informazioni: 115283
    Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
  3. Protocollo di studio
    Identificatore informazioni: 115283
    Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
  4. Rapporto di studio clinico
    Identificatore informazioni: 115283
    Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
  5. Modulo di consenso informato
    Identificatore informazioni: 115283
    Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
  6. Set di dati del singolo partecipante
    Identificatore informazioni: 115283
    Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
  7. Modulo di segnalazione del caso annotato
    Identificatore informazioni: 115283
    Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Fluticasone furoate 50mcg

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Israel

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi